If you are headed to BioCentury Inc.'s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development...
Next-gen TCR-based therapies against solid tumors have the power to disrupt and transform the development, delivery, and efficacy for cancer...
SAN DIEGO & SINGAPORE--(BUSINESS WIRE)--ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based...
ImmunoScape Leadership to Present at Upcoming Industry Conferences CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will...
The ImmunoScape team is heading to the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco in a few weeks. Our CEO Choon-Peng (Choon) Ng,...
Florian Schmidt, PhD will be presenting at the upcoming ISMB/ECCB 2023 conference in Lyon. On Thursday, July 27th Florian will describe...
Our team is headed to #bio2023 in Boston June 5-8! Our CEO Choon-Peng (Choon) Ng and our Senior Director, Business Development Christopher Alfonso...
Are you attending the 41st Annual JPM Healthcare Conference in San Francisco next month? Our CEO, Choon-Peng Ng, and Dan MacLeod, VP Discovery, will...
One of our senior scientists in discovery, Juliana Barclay, will be presenting at Society for Immunotherapy of Cancer (SITC) 2022 in Boston this...